The role of cellular senescence in ageing and endocrine disease

With the ageing of the global population, interest is growing in the 'geroscience hypothesis', which posits that manipulation of fundamental ageing mechanisms will delay (in parallel) the appearance or severity of multiple chronic, non-communicable diseases, as these diseases share the sam...

Full description

Saved in:
Bibliographic Details
Published in:Nature reviews. Endocrinology Vol. 16; no. 5; pp. 263 - 275
Main Authors: Khosla, Sundeep, Farr, Joshua N, Tchkonia, Tamara, Kirkland, James L
Format: Journal Article
Language:English
Published: England Nature Publishing Group 01.05.2020
Subjects:
Aging
Aging - physiology
Animals
Cellular Senescence
Clinical trials
Diabetes mellitus (non-insulin dependent)
Endocrine disorders
Endocrine System Diseases - etiology
Endocrine System Diseases - physiopathology
Endocrine System Diseases - prevention & control
Humans
Metabolic syndrome
Osteoporosis
Phenotypes
Risk Factors
Senescence
ISSN:1759-5029, 1759-5037, 1759-5037
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:With the ageing of the global population, interest is growing in the 'geroscience hypothesis', which posits that manipulation of fundamental ageing mechanisms will delay (in parallel) the appearance or severity of multiple chronic, non-communicable diseases, as these diseases share the same underlying risk factor - namely, ageing. In this context, cellular senescence has received considerable attention as a potential target in preventing or treating multiple age-related diseases and increasing healthspan. Here we review mechanisms of cellular senescence and approaches to target this pathway therapeutically using 'senolytic' drugs that kill senescent cells or inhibitors of the senescence-associated secretory phenotype (SASP). Furthermore, we highlight the evidence that cellular senescence has a causative role in multiple diseases associated with ageing. Finally, we focus on the role of cellular senescence in a number of endocrine diseases, including osteoporosis, metabolic syndrome and type 2 diabetes mellitus, as well as other endocrine conditions. Although much remains to be done, considerable preclinical evidence is now leading to the initiation of proof-of-concept clinical trials using senolytics for several endocrine and non-endocrine diseases.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1759-5029
1759-5037
1759-5037
DOI:10.1038/s41574-020-0335-y